Retraction Note: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability(Journal of Translational Medicine, (2008), 6, (27), 10.1186/1479-5876-6-27);Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Verdina, Alessandra ^a   Cardillo, Irene ^a   Nebbioso, Angela ^b   Galati, Rossella ^a   Menegozzo, Simona ^b   Altucci, Lucia ^b   Sacchi, Ada ^a   Baldi, Alfonso ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; PIROXICAM; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MESOTHELIOMA; MONOTHERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH; CELL CYCLE; CELL LINE; CELL SURVIVAL; DRUG EFFECT; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; ENZYME ACTIVATION; HUMANS; MESOTHELIOMA; PIROXICAM;

EID: 44949244913     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-022-03834-5     Document Type: Erratum

References (46)

1. Leaper DJ French B Bennett A Reduction by flurbiprofen of primary tumor growth and local metastasis formation in mice Adv Prostaglandin Thromboxane Res 1980, 6:591-3. 7386295
2. Waddel WR Loughry RW Sulindac for polyposis of the colon J Surg Oncol 1983, 24:83-7. 10.1002/jso.2930240119 6887943
3. Konturek PC Konturek SJ Bielanski W Kania J Zuchowicz M Hartwich A Rehfeld JF Hahn EG l Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients Dig Dis Sci 2003, 48:2005-17. 10.1023/A:1026387908165 14627349
4. Altorki NK Keresztes RS Port JL Libby DM Korst RJ Flieder DB Ferrara CA Yankelevitz DF Subbaramaiah K Pasmantier MW Dannenberg AJ Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer J Clin Oncol 2003, 21:2645-50. 10.1200/JCO.2003.07.127 12860939
5. Crane CH Mason K Janjan NA Milas L Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer Am J Clin Oncol 2003, 26:S81-4. 10.1097/ 00000421-200308002-00009 12902862
6. Pruthi RS Derksen JE Moore D A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy BJU Int 2004, 93:275-8. 10.1111/j.1464-410X.2004.04601.x 14764122
7. Sandler AB Dubinett SM COX-2 inhibition and lung cancer Semin Oncol 2004, 31:45-52. 10.1053/j.seminoncol.2004.03.045 15179623
8. Baron JA Epidemiology of non-steroidal anti-inflammatory drugs and cancer Prog Exp Tumor Res 2003, 37:1-24. 12795046
9. Vane JR Bakhle YS Botting RM Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 1998, 38:97-120. 10.1146/annurev.pharmtox.38.1.97 9597150
10. Chinery R Coffey RJ Graves-Deal R Kirkland SC Sanchez SC Zackert WE Oates JA Morrow JD Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells Cancer Res 1999, 59:2739-46. 10364000
11. Fosslien E Molecular pathology of cyclooxygenase-2 in neoplasia Ann Clin Lab Sci 2000, 30:3-21. 10678579
12. Nzeako UC Guicciardi ME Yoon JH Bronk SF Gores G COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells Hepatology 2002, 35:552-9. 10.1053/jhep.2002.31774 11870367
13. Tang X Sun YJ Half E Kuo MT Sinicrope F Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells Cancer Res 2002, 62:4903-8. 12208739
14. Kakiuchi Y Tsuji S Tsujii M Murata H Kawai N Yasumaru M Kimura A Komori M Irie T Miyoshi E Sasaki Y Hayashi N Kawano S Hori M Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis Cancer Res 2002, 62:1567-72. 11888937
15. Li G Yang T Yan J Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells Biochem Biophys Res Commun 2002, 299:886-90. 10.1016/S0006-291X(02)02707-9 12470662
16. Liu XH Kirschenbaum A Yao S Stearns ME Holland JF Claffey K Levine AC Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line Clin Exp Metastasis 1999, 17:687-94. 10.1023/A:1006728119549 10919714
17. Tegeder I Pfeilschifter J Geisslinger G Cyclooxygenase-independent actions of cyclooxygenase inhibitors FASEB J 2001, 15:2057-72. 10.1096/ fj.01-0390rev 11641233
18. Soh JW Weinstein IB Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment Prog Exp Tumor Res 2003, 37:261-85. 12795059
19. O'Kane SL Cawkwell L Campbell A Lind MJ Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma Eur J Cancer 2005, 41:1645-8. 10.1016/j.ejca.2005.04.019 15964184
20. Baldi A Santini D Vasaturo F Santini M Vicidomini G Di Marino MP Esposito V Groeger AM Liuzzi G Vincenzi B Tonini G Piccoli M Baldi F Scarpa S Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma Thorax 2004, 59:428-33. 1746992 15115874 10.1136/ thx.2003.008912
21. Edwards JG Faux SP Plummer SM Abrams KR Walker RA Waller DA O'Byrne KJ Abrams. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma Clin Cancer Res 2002, 6:1857-62.
22. Peto J Decarli A La Vecchia C Levi F Negri E The European mesothelioma epidemic Br. J Cancer 1999, 79:666-72. 10.1038/sj.bjc.6690105 10027347
23. Curran D Sahmoud T Therasse P van Meerbeeck J Postmus PE Giaccone G Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience J Clin Oncol 1998, 16:145-52. 9440736
24. Weder W Kestenholz P Taverna C Bodis S Lardinois D Jerman M Stahel RA Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma J Clin Oncol 2004, 22:3451-7. 10.1200/ JCO.2004.10.071 15337794
25. Vogelzang NJ Rusthoven JJ Symanowski J Denham C Kaukel E Ruffie P Gatzemeier U Boyer M Emri S Manegold C Niyikiza C Paoletti P Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 2003, 21:2636-44. 10.1200/JCO.2003.11.136 12860938
26. Van Meerbeeck JP Gaafar R Manegold C van Meerbeeck JP Gaafar R Manegold C Van Klaveren RJ Van Marck EA Vincent M Legrand C Bottomley A Debruyne C Giaccone G European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 2005, 23:6881-9. 10.1200/JCO.20005.14.589 16192580
27. Weder W Stahel RA Bernhard J Bodis S Vogt P Ballabeni P Lardinois D Betticher D Schmid R Stupp R Ris HB Jermann M Mingrone W Roth AD Spiliopoulos A Swiss Group for Clinical Cancer Research l Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma Ann Oncol 2007, 18:1196-202. 10.1093/annonc/mdm093 17429100
28. Marrogi A Pass HI Khan M Metheny-Barlow LJ Harris CC Gerwin BI Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2). and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effects of a COX-2 inhibitor Cancer Res 2000, 60:3696-700. 10919635
29. Catalano A Graciotti L Rinaldi L Raffaelli G Rodilossi S Betta P Gianni W Amoroso S Procopio A Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention Int J Cancer 2004, 109:322-8. 10.1002/ijc.11710 14961568
30. Spugnini EP Cardillo I Verdina A Crispi S Saviozzi S Calogero R Nebbioso A Altucci L Cortese G Galati R Chien J Shridhar V Vincenzi B Citro G Cognetti F Sacchi A Baldi A Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma Clin Cancer Res 2006, 12:6133-43. 10.1158/ 1078-0432.CCR-06-1056 17062690
31. Nebbioso A Clarke N Voltz E Germain E Ambrosino C Bontempo P Alvarez R Schiavone EM Ferrara F Bresciani F Weisz A de Lera AR Gronemeyer H Altucci L Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nat Med 2005, 11:77-84. 10.1038/nm1161 15619633
32. Altucci L Rossin A Raffelsberger W Reitmair A Chomienne C Gronemeyer H Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL Nat Med 2001, 6:680-6. 10.1038/89050
33. Tomek S Manegold C Chemotherapy for malignant pleural mesothelioma Curr Opin Oncol 2003, 15:148-56. 10.1097/00001622-200303000-00006 12601280
34. Kundu JK Choi KY Surh YJ β-catenin-mediated signalling: A novel molecular target for chemoprevention with anti-inflammatory substances Biochimica et Biophysica Acta 2006, 1765:14-24. 16226380
35. Bos CL Kodach LL Brink van den GR Diks SH van Santen MM Richel DJ Peppelenbosch MP Hardwick JC Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A Oncogene 2005, 25:6447-56. 10.1038/sj.onc.1209658
36. Maier TJ Janssen A Schmidt R Geisslinger G Grösch S Targeting the beta-catenin/APC pathway: A novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells FASEB J 2005, 19:1353-5. 15946992
37. Waddell WR Miesfeld RL Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: The effect of sulindac J Surg Oncol 1995, 58:252-6. 10.1002/jso.2930580411 7723369
38. Yamamoto Y Yin MJ Lin KM Gaynor RB Sulindac inhibits activation of the NF-kappaB pathway J Biol Chem 1999, 274:27307-14. 10.1074/ jbc.274.38.27307 10480951
39. Chan TA Morin PJ Vogelstein B Kinzler KW Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis Proc Natl Acad Sci USA 1998, 95:681-6. 18480 9435252 10.1073/pnas.95.2.681
40. Piazza GA Rahm AK Finn TS Fryer BH Li H Stoumen AL Pamukcu R Ahnen DJ Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition. Cell cycle arrest, and p53 induction Cancer Res 1997, 57:2452-9. 9192825
41. Dihlmann S Siermann A von Knebel Doeberitz M The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling Oncogene 2001, 20:645-653. 10.1038/ sj.onc.1204123 11313997
42. Mohammed SI Craig BA Mutsaers AJ Glickman NW Snyder PW deGortari AE Schlittler DL Coffman KT Bonney PL Knapp DW Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer Mol Cancer Ther 2003, 2(2):183-8. 12589035
43. Spugnini EP Crispi S Scarabello A Caruso G Citro G Baldi A Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: Preliminary observations J Exp Clin Cancer Res 2008, 27:6.
44. Baldi A Groeger AM Esposito V Cassandro R Tonini G Battista T Di Marino MP Vincenzi B Santini M Angelini A Rossiello R Baldi F Paggi MG Expression of p-21 in SV40 large T antigen positive human pleural mesothelioma: Relationship to survival Thorax 2002, 57:353-6. 1746306 11923556 10.1136/thorax.57.4.353
45. Spugnini EP Campioni M D'Avino A Caruso G Citro G Baldi A Cell-cycle molecules in mesothelioma, an overview J Exp Clin Cancer Res 2007, 26:515-521. 18365547
46. Spugnini EP Bosari S Citro G Lorenzon I Cognetti F Baldi A Human malignant mesothelioma: Molecular mechanisms of pathogenesis and progression Int J Biochem Cell Biol 2006, 38:2000-4. 10.1016/ j.biocel.2006.07.002 16963313